Boston Herald -- Sanofi-Aventis’ planned $20.1 billion purchase of Cambridge biotech giant Genzyme could lead to local cuts in administrative positions, but might also create new R&D and manufacturing jobs, Genzyme’s CEO says.
Genzyme chief Henri Termeer told the Herald yesterday that some of his company’s current jobs “related to the administration of a public company (are) probably not necessary” once Sanofi and Genzyme merge later this year.
